The therapeutic induction of immune tolerance has been demonstrated in several autoimmune disease models—for example, administration of myelin basic protein (MBP) has been shown to suppress disease onset in experimental autoimmune encephalomyelitis (17), while insulin peptide administration prevents the development of type 1 diabetes (18). This evidence concerns the gene MBP and type 1 diabetes mellitus.